



YOU ARE INVITED TO JOIN US FOR A CONTEMPORARY AND CLINICALLY RELEVANT EDUCATIONAL ACTIVITY.

This interactive and evidence-based program was developed by leading Canadian experts to address the importance of strict management of low density lipoprotein cholesterol (LDL-C) for patients with atherosclerotic cardiovascular disease as well as provide a timely review of the results of recently completed clinical trials and their applicability to routine clinical practice.

Join us for a group learning session

Date:

Location:

Program Start Time:

Program End Time:

*Meal to follow the presentation

Speaker (s):

RSVP:

AGENDA

The following modules will be presented:

- ☐ **New Horizons in Dyslipidemia Management in Primary Care**
- ☐ **Case 1:** - Diabetes & Cardiovascular Disease
- ☐ **Case 2:** - LDL-C: How Low Do You Go?
- ☐ **Case 3:** - ASCVD with Multiple CV Risk Factors
- ☐ **Case 4:** - Familial Hypercholesterolemia

LEARNING OBJECTIVES

Upon completion of this activity, participants will be able to:

- Discuss the role of LDL-C lowering in cardiovascular risk reduction with emphasis on the results of recently completed clinical trials
- Evaluate recommendations for lipid lowering agents beyond or in addition to statin therapy for patients with atherosclerotic cardiovascular disease
- Explain the mechanism of action of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and apply the latest clinical data to patient management strategies
- Apply best guideline practice recommendations into routine clinical practice based on specific patient characteristics

This one-credit-per-hour Group Learning program has been certified by the College of Family Physicians of Canada and the Chapter for up to Mainpro+ credits.

This program has received an educational grant and in-kind support from Amgen Canada

